|Articles|October 2, 2017
EFGCP Gives Priority to ‘Two Ends of Life’
Author(s)Philip Ward
Advertisement
The two ends of life can be viewed separately, but they have many common elements like frailty or vulnerability, and these shared aspects mean that geriatric and pediatric drug development should be viewed together, according to the European Forum for GCP (EFGCP).
This philosophy has inspired the Children’s Medicines and Geriatric Medicines Working Parties of the EFGCP to organize a joint meeting, called “Multi-Stakeholder Workshop on Facilitating Medicines Development for Youth and the ‘Young at Heart’: Learning for Intergenerational Strategies,” to be held in London on 21 November.
“The development of drugs is evolving and much effort is being put into understanding in special populations like children and older people,” noted a statement from the organizers. “The agenda reflects important topics like the special ethical considerations that can affect the informed consent process, evaluation of the safety parameters which is dependent of the adequate reporting of adverse events, and interpretation of the adverse drug reactions and proper use of modelling of simulation to bring value to the drug development process.”
The objective is to share challenges, to detect possible synergies, and to learn from each other to improve and facilitate high quality ethical clinical research and drug development for these populations across Europe, they added.
For more details about the event, click here .
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
- Q&A: Strategies for Successful Global Clinical Trial Delivery
September 12th 2025
- Vabysmo Shows Long-Term Efficacy and Safety in Wet AMD, PCV Patients
September 12th 2025
- Latest NIMBLE Study Results Highlight Progress in gMG Research
September 12th 2025
- ACT Brief Episode 8: Expert Insights on the Future of Obesity Drug Trials
September 11th 2025
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
FDA Fast Tracks Sanofi’s Intravitreal Gene Therapy for Neovascular Age-Related Macular Degeneration
2
Phase III BRUIN CLL-313 Trial Finds Jaypirca Extends Progression-Free Survival in Treatment-Naïve CLL/SLL
3
Latest NIMBLE Study Results Highlight Progress in gMG Research
4
ACT Brief Episode 8: Expert Insights on the Future of Obesity Drug Trials
5